Structure-based Design Used as Tool for Engineering Deimmunized Biotherapeutics
February 13, 2015
Dartmouth investigators engineer drug candidates for improved compatibility with immune system
In the first experimental use of algorithms that employ structure-based molecular modeling to optimize deimmunized drug candidates, Karl Griswold, PhD, and co-investigator Christopher Bailey-Kellogg, PhD of Dartmouth College complement their prior sequence-based deimmunizing algorithms and expand the tool kit of protein engineering technologies to use in next generation drug development. Their paper, "Protein Deimmunization via Structure-based Design Enables Efficient Epitope Deletion at High Mutational Loads," was published in Biotechnology and Bioengineering.
"This work is part of our larger collaborative initiative to develop performance-enhanced protein drugs that are invisible to the human immune system," explained Griswold. "Biotherapeutics offer potent treatment options for a wide range of diseases but, due to their biological origins, these powerful therapies can elicit detrimental immune responses in humans."
Development of biotherapeutic agents is a time-consuming and costly endeavor, and there exists a substantial risk that deleterious immunogenicity issues will undermine otherwise promising drug candidates late in the development process. While methods for identifying immunogenic hotspots, or epitopes, are evolving rapidly, technologies to redesign the hotspots while maintaining biotherapeutic activity and stability are far less developed.
This study used P99 betalactamase, a component of Antibody Directed Enzyme Prodrug Therapy, to show that structure-based deimmunization resulted in highly-active and stable biotherapeutic designs that were different from those generated with earlier sequence-based algorithms. In particular, the structure-based designs remodeled a putative immunogenic hotspot that was not readily addressed with other methods.
"We demonstrated that integrating molecular modeling into deimmunizing algorithms enables simultaneous redesign of numerous immunogenic hotspots distributed throughout a protein target," Bailey-Kellogg said. "These results suggest that even the most immunogenic drug candidates might be engineered for improved compatibility with the human immune system."
Dartmouth's team of Griswold and Bailey-Kellogg are turning their attention to advanced assays and methodologies to better assess the immunogenic potential of their deimmunized drug candidates. These methods should yield clinically relevant data showing the extent to which they have mitigated the immunogenicity risk of target proteins in the drug candidates.
Karl Griswold, PhD is Associate Professor of Engineering at the Thayer School of Engineering at Dartmouth. His work in cancer is facilitated by Dartmouth's Norris Cotton Cancer Center. Christopher Bailey-Kellogg, PhD is Professor of Computer Science at Dartmouth College. This work was funded by National Institutes of Health grant RO1-GM-098977, a Luce Foundation Fellowship, and National Science Foundation grant CNS-1205521.
About Norris Cotton Cancer Center at Dartmouth-Hitchcock
Norris Cotton Cancer Center combines advanced cancer research at Dartmouth and the Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center in Lebanon, NH, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute's "Comprehensive Cancer Center" designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.